Incidence and Prevalence of Overt Hypothyroidism and Causative Diseases in Korea as Determined Using Claims Data Provided by the Health Insurance Review and Assessment Service.
10.3803/EnM.2015.30.3.288
- Author:
Gi Hyeon SEO
1
;
Jae Hoon CHUNG
Author Information
1. Health Insurance Review and Assessment Service, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
Hypothyroidism;
Incidence;
Prevalence;
Korea
- MeSH:
Female;
Humans;
Hypothyroidism*;
Incidence*;
Insurance, Health*;
Korea*;
Male;
Prevalence*;
Retrospective Studies;
Thyroid Gland;
Thyroid Neoplasms
- From:Endocrinology and Metabolism
2015;30(3):288-296
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND: The incidence and prevalence of overt hypothyroidism have been reported to be 2 to 4/1,000 population/year and 8 to 13/1,000 population, respectively, in foreign countries. As there has been no nationwide survey to obtain data in Korea, the present study investigated the incidence and prevalence of overt hypothyroidism in Korea using claims data provided by the Health Insurance Review and Assessment Service. The proportions of causative diseases for hypothyroidism were also analyzed. METHODS: This study was retrospectively performed with 541,969 Korean patients (92,832 men and 449,137 women), with overt hypothyroidism, treated with thyroid hormone between 2008 and 2012. RESULTS: The incidence of overt hypothyroidism in Korea was 2.26/1,000 population/year (0.78 in men and 3.72 in women), and the prevalence was 14.28/1,000 population (4.40 in men and 24.03 in women). When patients with thyroid cancer were excluded, the incidence was 1.56/1,000 population/year (0.54 in men and 2.57 in women). The incidence increased with age, with peaks in and after the late 60s in men and in the early 50s in women. The prevalence peaked in the early 70s in men and in the late 50s in women. CONCLUSION: This is a report of the first nationwide investigation of the incidence and prevalence of overt hypothyroidism in Korea, although it is limited to patients treated with thyroid hormone.
